Kaiser Study Backs Cxbladder Triage Ahead of Medicare Panel

Core Insights - The publication of a study confirms the clinical value of Cxbladder, emphasizing its importance for payers, providers, and patients who may avoid unnecessary invasive procedures [1][4] - The study's findings will be considered by the Contractor Advisory Committee (CAC) for Medicare reimbursement decisions regarding Cxbladder tests, with a meeting scheduled for February 19, 2026 [1][4] Study Findings - The study demonstrated that Cxbladder Triage significantly reduced cystoscopy and imaging procedures for low and intermediate-risk patients while increasing appropriate procedures for higher-risk patients [2][3] - A total of 3,353 risk-matched patients were evaluated, showing a cystoscopy rate of 3.8% for low probability patients compared to 46.5% in the risk-matched group, and a rate of 73.4% for high probability patients versus 45.7% in the standard care group [6] - Cancer detection rates were similar between Cxbladder Triage patients and standard care patients (0.6% vs 0.7%), indicating that unnecessary procedures were reduced without compromising cancer detection [6] Company Overview - Pacific Edge Limited is a global cancer diagnostics company focused on bladder cancer diagnostic and prognostic tests, headquartered in Dunedin, New Zealand [5] - Cxbladder tests are available in the US, Australasia, Israel, and various markets in Asia and South America, with over 5,000 urologists in the US having ordered more than 130,000 tests [10] - The company has a strong evidence portfolio with over 25 peer-reviewed publications supporting Cxbladder, which is included in the American Urological Association's Microhematuria Guideline [9]